Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Julphar
Covington
Accenture
AstraZeneca
US Department of Justice
McKesson
Merck
Cantor Fitzgerald

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022465

« Back to Dashboard

NDA 022465 describes VOTRIENT, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the VOTRIENT profile page.

The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.
Summary for 022465
Tradename:VOTRIENT
Applicant:Novartis Pharms Corp
Ingredient:pazopanib hydrochloride
Patents:3
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 022465
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465 NDA Novartis Pharmaceuticals Corporation 0078-0670 N 0078-0670-66

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 200MG BASE
Approval Date:Oct 19, 2009TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 26, 2019
Regulatory Exclusivity Use:ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
Patent:➤ Sign UpPatent Expiration:Oct 19, 2023Product Flag?YSubstance Flag?YDelist Request?
Patent:➤ Sign UpPatent Expiration:Dec 19, 2021Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Express Scripts
McKesson
Mallinckrodt
Dow
Colorcon
UBS
QuintilesIMS
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot